Stuart Seiff, MD
Ophthalmology · San Francisco, CANPI 1114928561
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Amgen at 49.9% of the total. Reporting peaked in 2019 at $9,450 and has fallen 98.1% since, to $177 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $568.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$9K
- Genentech USA, Inc.$7K
- Genentech, Inc.$1K
- Sight Sciences, Inc.$261
- AbbVie$202
- Galderma Laboratories, L.p.$147
- plus $266 from 4 others
What the payments were for
- Consulting fees$7,55040%
- Speaking & faculty fees$7,85042%
- Travel & lodging$1,81010%
- Food & beverage$1,5528%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 16 | $9,363 |
| Genentech USA, Inc. | 5 | $7,174 |
| Genentech, Inc. | 1 | $1,350 |
| Sight Sciences, Inc. | 1 | $261 |
| AbbVie(2 entities) | 4 | $202 |
| Galderma Laboratories, L.p. | 2 | $147 |
| Mallinckrodt Enterprises LLC | 1 | $120 |
| Stryker | 1 | $79 |
| Revance Therapeutics, Inc. | 1 | $52 |
| Merz North America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enspryng$8,476
- OMNI(R) SURGICAL SYSTEM (US)$261
- ACTHAR$120
- BOTOX COSMETIC$110
How this compares
$18,762 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 397 | $3,839 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 151 | $2,058 |
| MoxifloxacinMoxifloxacin Hcl | 17 | $761 |
| Ketorolac Tromethamine | 14 | $445 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 29 | $258 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $119 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in San Francisco
- Daniel SchwartzSan Francisco$8M
- Gaurav ShahSan Francisco$620K
- Shan LinSan Francisco$374K
- H TanakaSan Francisco$238K
- Jay StewartSan Francisco$219K
- Scott SoSan Francisco$173K
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.